Cingulate (NASDAQ:CING) Upgraded at Wall Street Zen

Cingulate (NASDAQ:CING - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently commented on CING. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Cingulate in a report on Tuesday, May 26th. Ascendiant Capital Markets lowered their target price on shares of Cingulate from $55.00 to $52.00 and set a "buy" rating on the stock in a research note on Monday, June 8th. Weiss Ratings lowered shares of Cingulate from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 18th. Finally, Roth Capital set a $9.00 price target on shares of Cingulate and gave the stock a "buy" rating in a research note on Sunday, August 23rd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $27.00.

Cingulate Trading Down 2.2%

CING opened at $5.32 on Friday. The stock's 50 day simple moving average is $5.03 and its 200-day simple moving average is $5.54. The stock has a market cap of $77.35 million, a PE ratio of -1.48 and a beta of -0.90. Cingulate has a 1 year low of $3.16 and a 1 year high of $11.89.

Cingulate (NASDAQ:CING - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.18. Equities analysts forecast that Cingulate will post -2.31 earnings per share for the current fiscal year.

Institutional Trading of Cingulate

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC raised its holdings in shares of Cingulate by 14.8% in the first quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company's stock valued at $869,000 after buying an additional 18,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock worth $265,000 after acquiring an additional 18,629 shares during the last quarter. DRW Securities LLC acquired a new stake in Cingulate in the 4th quarter valued at about $255,000. BlackRock Inc. acquired a new position in shares of Cingulate during the second quarter worth approximately $291,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Cingulate during the first quarter worth approximately $198,000. 41.31% of the stock is currently owned by institutional investors and hedge funds.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source